JPRN-UMIN000010259已完成2 期
A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapy - Bi-weekly XELOX with Bevacizumab
Yamaguchi University Graduate School of Medicibe, Digestive surgery and surgical oncology0 个研究点目标入组 45 人开始时间: 2013年3月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Severe renal function disorder (2) History of serious drug hypersensitivity or a history of drug allergy (3) History of active double cancer within 5 years (4) Active infections (5) Distinctly abnormal ECG or cardiovascular disease (6) Cpmplication of thromboembolism,severe pulmonary disease(interstitial pneumonia, pulmonary fibrosis, mild Emphysema) "(7) complication of GI perforation or hemorrhage ,Paresis of intestine or intestinal obstruction " (8) Massive pleural effusion or ascites that required drainage (9) Brain metastasis (10) Complication of mental disorder,CNS disease, cerebrovascular disease. (11) Uncontrollable hypertension or diabetes mellitus (12) Uncontrollable diarrhea "(13) Patients with non-healing wounds,or surgery (thoracotomy, laparotomy) within 4 weeks " (14) Non-healing fracture (15) Bleeding diathesis or receiving anticoagulant drug(except Aspirin under 325mg/day) (16) Pregnant or lactating woman (17) Peripheral neuropathy (18) Other conditions not suitable for this study
研究者
相似试验
已完成
2 期
A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.nresectable advanced/recurrent colorectal cancerJPRN-UMIN000005060Fukuoka University Hospital100
已完成
2 期
Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancercolorectal cancerJPRN-UMIN000003500Epidemiological and Clinical Research Information Network (ECRIN)35
已完成
4 期
Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancerColorectal CancerJPRN-UMIN000003915Kyushu Study group of Clinical Cancer41
已完成
2 期
A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.Colorectal CancerJPRN-UMIN000006070Kyushu Study group of Clinical Cancer35
招募中
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancerJPRN-UMIN000011679Chubu Clinical Oncology Group25